Literature DB >> 31210614

Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma.

Jung Hee Son1, Sang Hyun Choi1, So Yeon Kim1, Hye Young Jang1, Jae Ho Byun1, Hyung Jin Won1, So Jung Lee1, Young Suk Lim1.   

Abstract

Background The 2017 version of the Liver Imaging Reporting and Data System (LI-RADS) recently included standardized interpretation, reporting, and management guidelines for US (US LI-RADS); however, this system has not yet been validated. Purpose To evaluate the diagnostic performance of US LI-RADS version 2017 for detecting hepatocellular carcinoma (HCC) in participants at high risk and to determine the clinical factors associated with a poor visualization score. Materials and Methods This study included 407 prospectively recruited participants (mean age, 56 years; age range, 28-76 years) with cirrhosis at high risk for HCC who underwent US surveillance from November 2011 to August 2012. Two radiologists retrospectively analyzed US images, assigning a LI-RADS category (US-1 = negative, US-2 = subthreshold, US-3 = positive) and a visualization score (A = no or minimal limitations, B = moderate limitations, C = severe limitations). The sensitivity and specificity for diagnosing HCC were calculated on a per-patient and per-lesion basis, using pathologic results and typical CT or MRI as reference standards. The risk factors for a poor visualization score were determined by using univariable and multivariable analyses. Results Of 429 lesions in 407 participants, there were 32 HCCs in 28 participants. In the per-lesion analysis, the specificity for US-3 was 366 of 397 (92%; 95% confidence interval [CI]: 89%, 95%) and the sensitivity was 11 of 32 (34%; 95% CI: 20%, 52%). In the per-patient analysis, the specificity for US-3 was 352 of 379 (93%; 95% CI: 90%, 95%) and the sensitivity was 11 of 28 (39%; 95% CI: 24%, 58%). Visualization score C (114 of 407 [28%] participants) had the highest false-negative rate (six of seven [86%] participants). High body weight (adjusted odds ratio [OR], 2.1 [95% CI: 1.2, 3.6]; P = .01), Child-Pugh class B disease (OR, 2.9 [95% CI: 1.7, 4.9]; P < .001), and moderate to severe fatty liver (OR, 1.7 [95% CI: 1.0, 2.8]; P = .047) were associated with a poor visualization score of C. Conclusion The US-3 category demonstrated high specificity but low sensitivity for diagnosing hepatocellular carcinoma. The visualization score C had a higher false-negative rate than scores A or B, and patients with high body weight, Child-Pugh class B disease, and moderate to severe fatty liver may present limitations for US surveillance. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Milot in this issue.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31210614     DOI: 10.1148/radiol.2019190035

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  8 in total

1.  Associations of Ultrasound LI-RADS Visualization Score With Examination, Sonographer, and Radiologist Factors: Retrospective Assessment in Over 10,000 Examinations.

Authors:  David T Fetzer; Travis Browning; Yin Xi; Takeshi Yokoo; Amit G Singal
Journal:  AJR Am J Roentgenol       Date:  2021-12-15       Impact factor: 6.582

2.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

3.  Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma.

Authors:  Xiang Zhou; Bin-Bin Cai; Xiang-Qing Hou; Xing-Kai Kang; Xiang-Xiang Xu; Wei-Ming Wang
Journal:  Aging (Albany NY)       Date:  2020-06-21       Impact factor: 5.682

4.  US LI-RADS visualization score: diagnostic outcome of ultrasound-guided focal hepatic lesion biopsy in patients at risk for hepatocellular carcinoma.

Authors:  Ji Hun Kang; Sang Hyun Choi; So Yeon Kim; So Jung Lee; Yong Moon Shin; Hyung Jin Won; Pyo-Nyun Kim
Journal:  Ultrasonography       Date:  2020-05-09

Review 5.  Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.

Authors:  Nia Adeniji; Renumathy Dhanasekaran
Journal:  Hepatol Commun       Date:  2021-09-17

Review 6.  Current Landscape and Future Perspectives of Abbreviated MRI for Hepatocellular Carcinoma Surveillance.

Authors:  Hyo Jung Park; Nieun Seo; So Yeon Kim
Journal:  Korean J Radiol       Date:  2022-04-13       Impact factor: 7.109

7.  Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B.

Authors:  Feng Su; Noel S Weiss; Lauren A Beste; Andrew M Moon; Ga-Young Jin; Pamela Green; Kristin Berry; George N Ioannou
Journal:  J Hepatol       Date:  2020-11-24       Impact factor: 25.083

8.  Current status of image-based surveillance in hepatocellular carcinoma.

Authors:  Dong Hwan Kim; Joon-Il Choi
Journal:  Ultrasonography       Date:  2020-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.